Histogen Inc (HSTO)

NASDAQ
1.4200
+0.0800(+5.97%)
After Hours
1.4200
0.0000(0.00%)
- Real-time Data
  • Volume:
    131,916
  • Day's Range:
    1.3400 - 1.4523
  • 52 wk Range:
    1.3000 - 15.9520

HSTO Overview

Prev. Close
1.34
Day's Range
1.34-1.4523
Revenue
4.36M
Open
1.34
52 wk Range
1.3-15.952
EPS
-5
Volume
131,916
Market Cap
3.55M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
882,146
P/E Ratio
-0.40
Beta
0.572
1-Year Change
-91.57%
Shares Outstanding
2,497,450
Next Earnings Date
Nov 15, 2022
What is your sentiment on Histogen Inc?
or
Market is currently closed. Voting is open during market hours.

Histogen Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Histogen Inc Analysis

Histogen Inc Company Profile

Histogen Inc Company Profile

Employees
22

Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing its hypoxia-generated growth factor technology platform and stem cell-free biologic products as restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. The Company's product pipelines include CCM Cosmetics, HST 003, HST 004, and Emricasan. In addition, within its small molecule pipeline, its product candidates also include CTS-2090 and CTS-2096. Its HST-003 is a human extracellular matrix (hECM), which is focused on regenerating hyaline cartilage for the treatment of articular cartilage defects in the knee, with a malleable scaffold that stimulates the body’s own stem cells. HST 004 is a cell conditioned medium (CCM) solution, which is used for treatment of spinal disc repair. Emricasan is an orally active pan-caspase inhibitor being developed for the treatment of COVID-19.

Read More

Analyst Price Target

Average5.0000 (+252.11% Upside)
High5
Low5
Price1.42
No. of Analysts1
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuyNeutralSellStrong Sell
Technical IndicatorsBuyStrong BuyBuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyNeutralStrong SellStrong Sell
  • What’s the bad news?
    0
    • Pt 47Trading at 90.9% below our estimate of its fair valueRevenue is forecast to grow 63.32% per yearRisk AnalysisEarnings have declined by 51.3% per year over past 5 yearsShareholders have been substantially diluted in the past yearDoes not have meaningful revenue ($1M)Does not have a meaningful market cap ($29M)
      0
      • last week to get in on evfm, before quarter results are in. expectedly good..
        1
        • DMA200 currently 1.3x setup for a GC move as well
          1
          • lets go🥳🚀🚀🚀
            1
            • I hope some of the guys losing hair from reddit due to GME going up and down start buying HSTO, plenty of shorting to fight here too.
              0
              • it's ON 🚀🚀
                1
              • that's the problem with pharma shares, they fall for a reason on firm's results of expts. if expt fails , share go down for a long time. so get out of it.
                0
            • is it going up soon?
              0
              • https://www.smarteranalyst.com/new-blurbs/histogen-hsto-has-a-new-rating-from-canaccord-genuity/
                0
                • Great news this week, seems like the alopecia treatment tests are still going great. I hope this stock can get back up and my hair back into my head and not in my shoulders or ears :D. I hope they can find something for those ones to migrate somewhere else haha
                  0
                  • I hope they get somewhere, it seems promising their work in knee cartilage regeneration and everyone will want to recover some of the hair lost from the stress of 2020 and 2021. Everyone bothered by losing hair or knee pain should invest here!
                    0